No clinical benefit seen from adding perifosine to capecitabine in patients with refractory metastatic colorectal cancer

Adding perifosine, an oral alkylphospholipid inhibitor, to oral capecitabine did not significantly change overall- or progression-free survival compared with capecitabine alone, according to data from the X-PECT study, presented by Dr Johanna Bendell of Sarah Cannon Research Institute, during the 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO), 1-5 June, Chicago. X-PECT is a phase III study that randomly assigned 468 patients with refractory colorectal cancer to receive perifosine/capecitabine (234 patients) or capecitabine (234 patients). Read more here.